MARKHAM, Ontario, March 15, 2024 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. ("Sienna" or the "Company") (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a "Common Share") for the month of March 2024, representing $0.936 per Common Share on an annualized basis.
The dividend will be payable on April 15, 2024 to shareholders of record as at March 29, 2024.
The Company's dividends are designated as eligible dividends for Canadian tax purposes in accordance with subsection 89(14) of the Income Tax Act (Canada), and any applicable corresponding provincial and territorial legislation.
About Sienna Senior Living
Sienna Senior Living Inc. (TSX:SIA) offers a full range of senior living options, including independent living, assisted living and memory care under its Aspira retirement brand, long-term care, and specialized programs and services. Sienna's approximately 12,000 employees are passionate about cultivating happiness in daily life. For more information, please visit www.siennaliving.ca.
For further information, please contact: David Hung Chief Financial Officer & Executive Vice President (905) 489-0258 [email protected]
Sisram Medical (1696.HK), a global leading innovator and provider of holistic medical aesthetic solutions announced today that the National Medical Products Administration has accepted the Biologics License Application ("BLA") for the Company's...
4M Therapeutics Inc. (4MTx), an early-stage biotechnology company developing treatments for neuropsychiatric and neurodegenerative diseases, today announced new preclinical data for its lead program, 4MT2001, a novel small molecule glycogen synthase...
Xencor, Inc. , a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced four new XmAb® programs in development for the treatment of patients with autoimmune...
Silexion Therapeutics has emerged an intriguing yet under the radar player in the precision oncology space, focusing on developing innovative RNA interference (RNAi) therapies for KRAS-driven cancers. As a recently de-SPACed company following its...
Agenus Inc. ("Agenus") , a leader in developing novel immunological agents to treat various cancers, today announced that updated data from the clinical trial of botensilimab and balstilimab in refractory sarcomas will be featured in a mini oral...
